Financial implications of CT-guided lung biopsy in a tertiary centre: a radiologists' perspective

Clin Radiol. 2021 Jun;76(6):447-451. doi: 10.1016/j.crad.2020.08.040. Epub 2021 Mar 7.

Abstract

Aim: To evaluate the financial costs of performing computed tomography (CT)-guided lung biopsies in a large tertiary centre to help guide service development.

Materials and methods: Local financial data were collected to create a balance sheet, considering all expenses as well as revenue sources associated with the procedure. Data were based on accurate pricing and income data and evaluated on a per-procedure basis, with consideration of additional costs arising from post-procedural complications. Revenue data were estimated based on reimbursement information. A small coding quality audit was also performed to check if reimbursement claims were filed correctly.

Results: This study demonstrated a healthy income generated from CT-guided lung biopsy procedures with a profit margin of 50%. Notably different financial impact was observed when comparing the same procedure undertaken on an outpatient as opposed to inpatient basis with inpatient procedures generating a net loss of - £2,146.79 a year. Overall, the activity generated a profit of £157,015.25, after accounting for loss generated by inpatient activity.

Conclusion: This analysis furthered understanding of the financial impact from performing CT-guided lung biopsy and will enable better planning and expansion of the service in the future, with emphasis around day-case and ambulatory service development, the positive intended consequence being an improved patient pathway.

MeSH terms

  • Attitude of Health Personnel*
  • Cost-Benefit Analysis / economics
  • Cost-Benefit Analysis / methods*
  • Humans
  • Image-Guided Biopsy / economics
  • Radiography, Interventional / economics*
  • Radiologists / statistics & numerical data*
  • Tertiary Care Centers*
  • Tomography, X-Ray Computed / economics*